Non-invasive refractive treatment using nanoparticles

Patent metadata

Field	Value
Publication number	US-11033380-B2
Application number	US-201715470785-A
Country	US
Kind code	B2
Filing date	Mar 27, 2017
Priority date	Mar 15, 2013
Publication date	Jun 15, 2021
Grant date	Jun 15, 2021

Abstract

Embodiments of this invention generally relate to systems and methods for optical treatment and more particularly to non-invasive refractive treatment method based on sub wavelength particle implantation. In an embodiment, a method for optical treatment identifies an optical aberration of an eye, determines a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye.

First claim

What is claimed is:

1. A system for optical treatment of an eye, the system comprising:
a delivery device; and
dopant operably coupled with the delivery device so as to be deliverable from the delivery device into the eye in a dopant pattern, wherein the dopant comprises a plurality of nanoparticles, wherein each nanoparticle is either a metallic nanoparticle producing surface plasmon effects, or a nanoparticle formed of an inorganic polymer with an inorganic transparent material embedded in the inorganic polymer;
wherein the delivery device is configurable to deliver the dopant into the eye so that the dopant pattern locally changes a refractive index of the eye so as to impose a desired correction to the eye to mitigate an optical aberration of the eye.

2. The system of claim 1 , wherein the optical aberration of the eye comprises one of a myopia, a hyperopia, and a regular astigmatism.

3. The system of claim 1 , wherein the optical aberration of the eye comprises a higher order aberration.

4. The system of claim 1 , wherein the correction identifies changes to the index of refraction in the cornea of the eye.

5. The system of claim 1 , wherein the delivery device includes a contact lens configured for placement on a portion of the eye, the contact lens having dopant carrier which releasably carries the dopant.

6. The system of claim 5 , wherein the dopant is released when activated, and wherein the activation of the dopant includes change in shape, composition, and/or properties of the dopant and/or the dopant carrier.

7. The system of claim 5 , wherein the dopant carried by the dopant carrier on a portion of the contact lens is released when the portion of the contact lens is irradiated.

8. The system of claim 5 , wherein the dopant located on portions of the contact lens is configured to diffuse into the cornea.

9. The system of claim 5 , wherein the dopant is configured to implant in the corneal stroma.

10. The system of claim 5 , wherein the dopant is uniformly distributed throughout the contact lens.

11. The system of claim 5 , wherein the dopant is non-uniformly distributed throughout the contact lens.

12. The system of claim 5 , wherein the contact lens comprises an orienting feature configured to orient the contact lens on the eye.

13. The system of claim 1 , wherein the inorganic transparent material is ZrO 2 .

14. The system of claim 1 , wherein the nanoparticles have a refractive index higher than a refractive index of a cornea of the eye.

Assignees

• Amo Dev Llc

Inventors

• Raymond Thomas D
• Copland Richard J

Classifications

• A61K9/0051

  Ocular inserts or implants · CPC title

• A61F2250/0067

  Means for introducing or releasing pharmaceutical products into the body · CPC title

• A61F2/147 Primary

  Implants to be inserted in the stroma for refractive correction, e.g. ring-like implants · CPC title

• A61F2/14 Primary

  Eye parts, e.g. lenses or corneal implants; Artificial eyes · CPC title

• A61F2/145

  Corneal inlays, onlays, or lenses for refractive correction · CPC title